Key Finding: A study published in Immunity by researchers at Memorial Sloan Kettering Cancer Center (MSK) has identified the signaling molecule MEK as a key regulator of T cell exhaustion, a major obstacle in cancer immunotherapy. The research, based on animal models, suggests that blocking MEK could improve the durability of T cell responses.
Mechanism
T cell exhaustion occurs when continuous exposure to tumor antigens places excessive metabolic demand on T cells. The study found that hyperactive MEK signaling drives T cells to invest excessive energy into producing cytotoxic proteins, leading to a terminally exhausted state. Inhibiting MEK reduced this energy expenditure, allowing T cells to persist longer even under the harsh tumor microenvironment.
Clinical Implications
The researchers propose that MEK inhibitors, already FDA-approved for other uses, could enhance several immunotherapies, including checkpoint inhibitors, CAR T cell therapy, TIL therapy, and bispecific antibodies. The strategy may be particularly beneficial for patients with large tumors or few tumor-reactive T cells, where a sustained but less intense immune response is needed.
Caveats
"MEK inhibition is a double-edged sword: it weakens the attack but extends T cell survival."
— Dr. Santosha Vardhana, Senior Author
The approach should be selectively applied based on tumor size and immune cell numbers. Patients with small tumors and many infiltrating T cells may not benefit from MEK inhibition and could be treated with standard immunotherapy.
Authors
The study was led by Tanmana Mitra, PhD, as first author, with additional authors including Jahan Rahman, Madeline Hwee, Yan-Ting Chen, Ruben Jose Jesus Faustino Ramos, Hui Liu, Travis Hartman, Justin Cross, Miguel de Jesus, Morgan Huse, Valerie Longo, and Pat Zanzonico.